NASDAQ: NKTX

Nkarta, Inc.

Healthcare | Biotechnology

No licensed closing price on file for NKTX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Nkarta, Inc. (NASDAQ: NKTX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 05:23 UTC.

What Nkarta, Inc. does

The company is a clinical-stage biopharmaceutical firm developing allogeneic, off-the-shelf engineered natural killer cell therapies, with a focus on CAR NK cell products. The lead program, NKX019, targets the CD19 antigen and is being studied in multiple Phase 1 clinical trials for autoimmune diseases including lupus nephritis, primary membranous nephropathy, systemic sclerosis, myositis, and vasculitis, as well as in investigator-sponsored trials for systemic lupus erythematosus and myasthenia gravis.

Summarized from Nkarta, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	8-K 2026-06-11
Return on equity	82.71%

Charts

Charts are in the appInteractive charts for NKTX are available in Oxford Ledge.
Open NKTX in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity

Source: SEC EDGAR · Filed 2026-06-22

Most recent filed transactions — June 2026:

2026-06-22Chief Executive OfficerSale-1,776$4.8K
2026-06-11DirectorStock Option (right to buy)Award37,000—
2026-06-11DirectorStock Option (right to buy)Award37,000—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

RA CAPITAL MANAGEMENT, L.P.10,805,129$30.58M0.0%
BlackRock, Inc.6,300,212$17.83M+39.7%
NEA Management Company, LLC3,568,781$10.10M0.0%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2024-07-16Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2023-03-30Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersNadir MahmoodAuthoritativeSEC 8-K →
2022-05-16Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersKanya RajangamEstimatedSEC 8-K →

Company news

View all →

Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
marketbeat.com2026-09-27
Nkarta: 'Hold' NKX019 Discontinuation For R/R NHL And Pivot To Autoimmune Disorders
Seeking Alpha Feed2026-09-03
Nkarta GAAP EPS of -$0.54 misses by $0.16
Seeking Alpha Markets2026-08-10NEG
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
globenewswire.com2026-06-26

Questions this page answers

What does Nkarta, Inc. do?

The company is a clinical-stage biopharmaceutical firm developing allogeneic, off-the-shelf engineered natural killer cell therapies, with a focus on CAR NK cell products.

When did NKTX last file with the SEC?

Nkarta, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-11. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 05:23 UTC. This page is also available as JSON at /api/data?ticker=NKTX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for NKTX and 5,000+ tickers.

Create a free account — keep NKTX

For your agent

GET /api/data?ticker=NKTX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt